O	0	4	Long
O	4	5	-
O	5	9	term
B-intervention	10	14	Diet
O	15	18	and
O	19	28	Biomarker
O	29	36	Changes
O	37	42	after
O	43	44	a
O	45	50	Short
O	50	51	-
O	51	55	term
O	56	68	Intervention
O	69	74	among
B-ethinicity	75	83	Hispanic
O	84	90	Breast
O	91	97	Cancer
O	98	107	Survivors
O	107	108	:
O	109	112	The
O	113	114	¡
O	114	121	Cocinar
O	122	126	Para
O	127	129	Su
O	130	135	Salud
O	135	136	!

O	137	147	Randomized
O	148	158	Controlled
O	159	164	Trial
O	164	165	.

O	166	171	Among
O	172	180	Hispanic
O	181	187	breast
O	188	194	cancer
O	195	204	survivors
O	204	205	,
O	206	208	we
O	209	217	examined
O	218	221	the
O	222	226	long
O	226	227	-
O	227	231	term
O	232	239	effects
O	240	242	of
O	243	244	a
O	245	250	short
O	250	251	-
O	251	255	term
O	256	266	culturally
O	267	272	based
O	273	280	dietary
O	281	293	intervention
O	294	296	on
O	297	307	increasing
O	308	314	fruits
O	314	315	/
O	315	325	vegetables
O	326	327	(
O	327	328	F
O	328	329	/
O	329	330	V
O	330	331	)
O	331	332	,
O	333	343	decreasing
O	344	347	fat
O	347	348	,
O	349	352	and
O	353	361	changing
O	362	372	biomarkers
O	373	383	associated
O	384	388	with
O	389	395	breast
O	396	402	cancer
O	403	413	recurrence
O	414	418	risk
O	418	419	.

B-eligibility	420	427	Spanish
I-eligibility	427	428	-
I-eligibility	428	436	speaking
I-eligibility	437	442	women
O	443	444	(
O	444	445	n
O	446	447	=
B-total-participants	448	450	70
O	450	451	)
B-eligibility	452	456	with
I-eligibility	457	458	a
I-eligibility	459	466	history
I-eligibility	467	469	of
I-eligibility	470	475	stage
I-eligibility	476	477	0
I-eligibility	477	478	-
I-eligibility	478	481	III
I-eligibility	482	488	breast
I-eligibility	489	495	cancer
I-eligibility	496	499	who
I-eligibility	500	509	completed
I-eligibility	510	519	treatment
O	520	524	were
O	525	535	randomized
O	536	538	to
O	539	540	¡
O	540	547	Cocinar
O	548	552	Para
O	553	555	Su
O	556	561	Salud
O	561	562	!

O	563	564	(
O	564	565	n
O	566	567	=
B-intervention-participants	568	570	34
O	570	571	)
O	571	572	,
O	573	574	a
O	575	585	culturally
O	586	591	based
O	592	593	9
O	593	594	-
O	594	601	session
O	602	609	program
O	610	611	(
O	611	613	24
O	614	619	hours
O	620	624	over
O	625	627	12
O	628	633	weeks
O	633	634	,
O	635	644	including
O	645	654	nutrition
O	655	664	education
O	664	665	,
O	666	673	cooking
O	674	681	classes
O	681	682	,
O	683	686	and
O	687	691	food
O	691	692	-
O	692	700	shopping
O	701	706	field
O	707	712	trips
O	712	713	)
O	713	714	,
O	715	717	or
O	718	719	a
B-control	720	727	control
O	728	733	group
O	734	735	(
O	735	736	n
O	737	738	=
B-control-participants	739	741	36
O	741	742	,
O	743	750	written
O	751	758	dietary
O	759	774	recommendations
O	775	778	for
O	779	785	breast
O	786	792	cancer
O	793	802	survivors
O	802	803	)
O	803	804	.

O	805	809	Diet
O	810	817	recalls
O	817	818	,
O	819	826	fasting
O	827	832	blood
O	832	833	,
O	834	837	and
O	838	852	anthropometric
O	853	861	measures
O	862	866	were
O	867	876	collected
O	877	879	at
O	880	888	baseline
O	888	889	,
O	890	891	6
O	891	892	,
O	893	896	and
O	897	899	12
O	900	906	months
O	906	907	.

O	908	910	We
O	911	917	report
O	918	925	changes
O	926	933	between
O	934	940	groups
O	941	943	at
O	944	946	12
O	947	953	months
O	954	956	in
O	957	964	dietary
O	965	971	intake
O	972	975	and
O	976	986	biomarkers
O	987	992	using
O	993	994	2
O	994	995	-
O	995	1001	sample
O	1002	1010	Wilcoxon
O	1011	1012	t
O	1013	1018	tests
O	1019	1022	and
O	1023	1034	generalized
O	1035	1045	estimating
O	1046	1054	equation
O	1055	1056	(
O	1056	1059	GEE
O	1059	1060	)
O	1061	1067	models
O	1067	1068	.

O	1069	1071	At
O	1072	1074	12
O	1075	1081	months
O	1081	1082	,
O	1083	1086	the
O	1087	1099	intervention
O	1100	1105	group
O	1106	1114	compared
O	1115	1119	with
O	1120	1123	the
O	1124	1131	control
O	1132	1137	group
O	1138	1146	reported
O	1147	1153	higher
O	1154	1163	increases
O	1164	1166	in
B-outcome	1167	1171	mean
I-outcome	1172	1177	daily
I-outcome	1178	1179	F
I-outcome	1179	1180	/
I-outcome	1180	1181	V
I-outcome	1182	1190	servings
O	1191	1192	(
O	1192	1197	total
O	1197	1198	:
B-iv-cont-mean	1199	1200	+
I-iv-cont-mean	1200	1201	2
I-iv-cont-mean	1201	1202	.
I-iv-cont-mean	1202	1203	0
O	1204	1206	vs
O	1206	1207	.
B-cv-cont-mean	1208	1209	-
I-cv-cont-mean	1209	1210	0
I-cv-cont-mean	1210	1211	.
I-cv-cont-mean	1211	1212	4
O	1212	1213	;
O	1214	1215	P
O	1216	1217	<
O	1218	1219	0
O	1219	1220	.
O	1220	1222	01
O	1222	1223	)
O	1223	1224	,
O	1225	1228	and
O	1229	1243	nonsignificant
O	1244	1253	decreases
O	1254	1256	in
O	1257	1260	the
B-outcome	1261	1271	percentage
I-outcome	1272	1274	of
I-outcome	1275	1283	calories
I-outcome	1284	1288	from
I-outcome	1289	1292	fat
O	1293	1294	(
B-iv-cont-mean	1294	1295	-
I-iv-cont-mean	1295	1296	2
I-iv-cont-mean	1296	1297	.
I-iv-cont-mean	1297	1298	2
I-iv-cont-mean	1298	1299	%
O	1300	1302	vs
O	1302	1303	.
B-cv-cont-mean	1304	1305	-
I-cv-cont-mean	1305	1306	1
I-cv-cont-mean	1306	1307	.
I-cv-cont-mean	1307	1308	1
I-cv-cont-mean	1308	1309	%
O	1309	1310	;
O	1311	1312	P
O	1313	1314	=
O	1315	1316	0
O	1316	1317	.
O	1317	1319	69
O	1319	1320	)
O	1321	1324	and
B-outcome	1325	1331	weight
O	1332	1333	(
B-iv-cont-mean	1333	1334	-
I-iv-cont-mean	1334	1335	2
I-iv-cont-mean	1335	1336	.
I-iv-cont-mean	1336	1337	6
I-iv-cont-mean	1338	1340	kg
O	1341	1343	vs
O	1343	1344	.
B-cv-cont-mean	1345	1346	-
I-cv-cont-mean	1346	1347	1
I-cv-cont-mean	1347	1348	.
I-cv-cont-mean	1348	1349	5
I-cv-cont-mean	1350	1352	kg
O	1352	1353	;
O	1354	1355	P
O	1356	1357	=
O	1358	1359	0
O	1359	1360	.
O	1360	1362	56
O	1362	1363	)
O	1363	1364	.

O	1365	1373	Compared
O	1374	1378	with
O	1379	1387	controls
O	1387	1388	,
O	1389	1401	participants
O	1402	1404	in
O	1405	1408	the
O	1409	1421	intervention
O	1422	1427	group
O	1428	1431	had
O	1432	1438	higher
O	1439	1448	increases
O	1449	1451	in
B-outcome	1452	1458	plasma
I-outcome	1459	1465	lutein
O	1466	1467	(
B-iv-cont-mean	1467	1468	+
I-iv-cont-mean	1468	1470	20
I-iv-cont-mean	1470	1471	.
I-iv-cont-mean	1471	1472	4
I-iv-cont-mean	1472	1473	%
O	1474	1476	vs
O	1476	1477	.
B-cv-cont-mean	1478	1479	-
I-cv-cont-mean	1479	1481	11
I-cv-cont-mean	1481	1482	.
I-cv-cont-mean	1482	1483	5
I-cv-cont-mean	1483	1484	%
O	1484	1485	;
O	1486	1487	P
O	1488	1489	<
O	1490	1491	0
O	1491	1492	.
O	1492	1494	01
O	1494	1495	)
O	1495	1496	,
O	1497	1500	and
O	1501	1511	borderline
O	1512	1523	significant
O	1524	1533	increases
O	1534	1536	in
B-outcome	1537	1543	global
I-outcome	1544	1547	DNA
I-outcome	1548	1559	methylation
O	1560	1561	(
B-iv-cont-mean	1561	1562	+
I-iv-cont-mean	1562	1563	0
I-iv-cont-mean	1563	1564	.
I-iv-cont-mean	1564	1565	8
I-iv-cont-mean	1565	1566	%
O	1567	1569	vs
O	1569	1570	.
B-cv-cont-mean	1571	1572	-
I-cv-cont-mean	1572	1573	0
I-cv-cont-mean	1573	1574	.
I-cv-cont-mean	1574	1575	5
I-cv-cont-mean	1575	1576	%
O	1576	1577	;
O	1578	1579	P
O	1580	1581	=
O	1582	1583	0
O	1583	1584	.
O	1584	1586	06
O	1586	1587	)
O	1587	1588	.

O	1589	1592	The
O	1593	1598	short
O	1598	1599	-
O	1599	1603	term
O	1604	1605	¡
O	1605	1612	Cocinar
O	1613	1617	Para
O	1618	1620	Su
O	1621	1626	Salud
O	1626	1627	!

O	1628	1635	program
O	1636	1639	was
O	1640	1649	effective
O	1650	1652	at
O	1653	1663	increasing
O	1664	1668	long
O	1668	1669	-
O	1669	1673	term
O	1674	1675	F
O	1675	1676	/
O	1676	1677	V
O	1678	1684	intake
O	1685	1687	in
O	1688	1696	Hispanic
O	1697	1703	breast
O	1704	1710	cancer
O	1711	1720	survivors
O	1721	1724	and
O	1725	1732	changed
O	1733	1743	biomarkers
O	1744	1754	associated
O	1755	1759	with
O	1760	1766	breast
O	1767	1773	cancer
O	1774	1784	recurrence
O	1785	1789	risk
O	1789	1790	.

O	1791	1793	It
O	1794	1796	is
O	1797	1805	possible
O	1806	1809	for
O	1810	1815	short
O	1815	1816	-
O	1816	1820	term
O	1821	1831	behavioral
O	1832	1845	interventions
O	1846	1848	to
O	1849	1853	have
O	1854	1858	long
O	1858	1859	-
O	1859	1863	term
O	1864	1871	effects
O	1872	1874	on
O	1875	1884	behaviors
O	1885	1888	and
O	1889	1899	biomarkers
O	1900	1902	in
O	1903	1911	minority
O	1912	1918	cancer
O	1919	1926	patient
O	1927	1938	populations
O	1938	1939	.

O	1940	1947	Results
O	1948	1951	can
O	1952	1958	inform
O	1959	1965	future
O	1966	1971	study
O	1972	1979	designs
O	1979	1980	.

O	1981	1987	Cancer
O	1988	1997	Epidemiol
O	1998	2008	Biomarkers
O	2009	2013	Prev
O	2013	2014	;
O	2015	2017	25
O	2017	2018	(
O	2018	2020	11
O	2020	2021	)
O	2021	2022	;
O	2023	2027	1491
O	2027	2028	-
O	2028	2031	502
O	2031	2032	.

O	2033	2034	©
O	2034	2038	2016
O	2039	2043	AACR
O	2043	2044	.
